NMRA today
$0.43-$0.04 (-8.46%)close Nov 12, 2026Trend
DailyUptrend (starting)
4 hourStrong Bearish
1 hourStrong Bearish
15 minExpanding
5 minSymmetric Triangle
Daily trend turns down below $0.32
Key levels
Resistance$0.65
Resistance$0.51
Support$0.36
Latest news & SEC filings
EarningsNeumora Therapeutics sets date for third-quarter 2026 earnings release
LegalNeumora Therapeutics gets Nasdaq noncompliance notice
SEC FilingNeumora Therapeutics, Inc. filed a report on a major company event (Form 8-K)
All NMRA news →About Neumora Therapeutics
Neumora Therapeutics is a clinical-stage biopharmaceutical company developing therapies for brain and central nervous system disorders. Its pipeline includes navacaprant, an oral kappa opioid receptor antagonist in Phase 3 testing for major depressive disorder, and NMRA-511, a vasopressin 1a receptor antagonist being studied for agitation in Alzheimer's disease. The company also has earlier-stage programs targeting schizophrenia, obesity, Parkinson's disease, and ALS, and operates primarily in the United States.
Based on the company's 10-K filed Mar 30, 2026.
Nasdaq · Healthcare
Neumora Therapeutics, Inc. (NMRA)
What Is the Price Target for NMRA?
SEPT Low Target
$4.00
SEPT Mid Target
$5.00
SEPT High Target
$5.00
Analyst Consensus
$5.00
Is NMRA a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for NMRA.
Start Free Trial →Is NMRA Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$3.91
7
Moat Score
NONE
1/9
Piotroski Score
-11.3
Altman Z-Score
What Is Smart Money Doing with NMRA?
Insider Signal
SELLING
0 buys / 4 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →NMRA Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
5.23%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for NMRA
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for NMRA, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:23 | $0.43 | 5,196 | $$2K | SELL |
| 20:59:57 | $0.44 | 1,700 | $$745 | BUY |
| 20:58:57 | $0.44 | 1,500 | $$662 | SELL |
| 20:45:34 | $0.45 | 1,061 | $$479 | BUY |
| 20:44:48 | $0.45 | 2,100 | $$952 | MIDPOINT |
5 dark pool trades shown · $$5K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Neumora Therapeutics, Inc. (NMRA) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →NMRA — frequently asked questions
What is NMRA stock price today?
Neumora Therapeutics, Inc. (NMRA) is at $0.43, down 8.46% (-$0.04) at the Nov 12, 2026 close.
Why is NMRA stock moving today?
Latest NMRA news — Nov 4, 2026: Neumora Therapeutics sets date for third-quarter 2026 earnings release · Oct 31, 2026: Neumora Therapeutics gets Nasdaq noncompliance notice
What is the NMRA price target?
The average analyst price target for NMRA is $5.00, ranging from $4 to $5, based on 3 analysts. Latest: RBC Capital maintains on Jul 13, 2026.
What do analysts rate NMRA?
Analyst ratings for NMRA: 0 Buy, 6 Hold, 0 Sell — consensus Hold.
Did NMRA beat earnings?
NMRA last reported on Aug 14, 2026: EPS -$0.23 vs -$0.24 expected — a beat of 4.2%.
Does NMRA pay a dividend?
NMRA does not currently pay a dividend.
How much debt does NMRA have?
Neumora Therapeutics, Inc. reported $53M of debt and $117M of cash (Jun 30, 2026).
What are NMRA support and resistance levels?
Support: $0.36. Resistance: $0.51, $0.65, $0.75.
What are insiders doing with NMRA?
Insider activity: SELLING, 0 buys and 4 sells in the last 90 days.
What is the latest news on NMRA?
Nov 4, 2026: Neumora Therapeutics sets date for third-quarter 2026 earnings release · Oct 31, 2026: Neumora Therapeutics gets Nasdaq noncompliance notice · Oct 30, 2026: Neumora Therapeutics, Inc. filed a report on a major company event (Form 8-K)